Sino Biopharmaceutical wins approval for Parkinson's patch in China

Sino Biopharmaceutical Limited announced that its Rotigotine Patch has received marketing approval from China's National Medical Products Administration. This transdermal patch is indicated for monotherapy for early idiopathic Parkinson's disease symptoms and signs, and for use in combination with levodopa at various stages of the disease. The approval addresses a significant medical need, as the number of Parkinson's disease patients in China is projected to exceed 5 million by 2025.

The Rotigotine patch is a non-ergot dopamine receptor agonist delivered transdermally, offering sustained drug concentration for 24 hours while avoiding hepatic first-pass effects. This method aims to reduce "off-periods" and prolong "on-periods" for patients experiencing the "on-off" phenomenon, improving symptom control and patient compliance. The group also highlighted that Rotigotine patch is included in several treatment guidelines, including the "Guidelines for the Treatment of Parkinson's Disease in China."

This approval marks another key achievement for Sino Biopharmaceutical's proprietary solvent-based transdermal patch platform, following the rivastigmine transdermal patch for Alzheimer's disease. The company anticipates over 10 patch products in its pipeline to be approved for marketing by 2030, further strengthening its leadership in transdermal patch technologies.